A week of antibiotics matched a month for orthopaedic infection

Patients treated for a bone or joint infection have long been sent home on weeks of antibiotics. A trial published in the New England Journal of Medicine now reports that, when a local-antibiotic carrier is placed at the surgical site, a systemic course of seven days or fewer was no worse than one of four weeks or more — and left patients with markedly fewer drug-related symptoms [s1].

Why the question matters

Orthopaedic infection — of a joint replacement, a fracture-fixation device, or the bone itself — is usually managed with surgery followed by prolonged systemic antibiotics [s1]. Those long courses carry their own costs: side effects, the logistics of intravenous lines, and the selection pressure that drives antimicrobial resistance. What the SOLARIO trial tested is whether antibiotics delivered directly into the wound by an implanted carrier can let the systemic course be cut short without raising the risk that the infection returns [s1].

What they did

SOLARIO was a multicentre, open-label, non-inferiority trial [s1]. It enrolled adults who had undergone surgery for an orthopaedic infection and implantation of a local-antibiotic carrier, then randomly assigned them in a 1:1 ratio to postoperative systemic antibiotics for a long duration — four weeks or more — or a short one, seven days or fewer [s1]. The trial was run across multiple sites and registered as SOLARIO, the Short or Long Antibiotic Regimes in Orthopaedics study [s2]. The local carrier is the pivot of the whole design: it delivers antibiotic straight into the tissue where infection lingers, which is the mechanism by which the systemic course might safely be shortened. The primary outcome was definite treatment failure by 12 months, judged against protocol criteria by an endpoint committee whose members did not know which group a patient was in [s1]. Non-inferiority is a deliberately modest claim: it asks whether the shorter course is not meaningfully worse, and the trial set that margin at 10 percentage points [s1].

What it showed

A total of 500 patients underwent randomisation, of whom 475 were assessed in the primary analysis [s1]. Definite treatment failure occurred in 34 of 241 patients (14.1%) in the long-duration group and in 26 of 234 patients (11.1%) in the short-duration group — a risk difference, with negative values favouring the short course, of −3.0 percentage points (95% confidence interval, −9.0 to 3.0), which met the prespecified non-inferiority margin [s1]. Sensitivity analyses told the same story: in the included population of 497 patients the risk difference was −2.4 percentage points (95% confidence interval, −8.2 to 3.5), and in the per-protocol population of 457 patients it was −2.7 percentage points (95% confidence interval, −8.8 to 3.4) [s1].

The clearer separation was in harm, not efficacy. By six weeks after surgery, symptoms potentially related to treatment had occurred in 45.2% of the long-duration patients but only 17.2% of the short-duration patients — a risk difference of −28.0 percentage points (95% confidence interval, −36.4 to −19.6) [s1]. Fewer weeks of drug meant fewer patients feeling the effects of it, with no signal that the infection was more likely to come back.

How to read it

Several cautions belong on this result. The confidence interval around the primary difference runs from −9.0 to 3.0 percentage points, so the data are compatible with the short course being slightly better or somewhat worse — non-inferiority means the upper edge stayed inside the agreed margin, not that the two courses were proven identical [s1]. The finding is also conditional: every patient received a local-antibiotic carrier at surgery, so it does not license shorter systemic courses when no local antibiotic is used [s1]. And the trial was open-label, meaning patients and treating clinicians knew the assignment, though the committee adjudicating failure did not [s1].

What sets the study apart from much drug-duration research is who paid for it. SOLARIO was funded by the European Bone and Joint Infection Society and other non-commercial backers rather than a drug manufacturer [s1] — an independent test of using less antibiotic, the kind of question companies rarely have reason to fund. That framing matters because shorter, carrier-supported courses would mean lower drug volumes, not higher.

What to watch

The immediate open question is durability: SOLARIO measured failure at 12 months, and orthopaedic infections can recur later, so longer follow-up will show whether the equivalence holds. The result also invites replication in settings and infection types beyond those enrolled, and in patients who do not receive a local carrier. For now, the trial adds to a broad shift in infectious-disease practice — the accumulating evidence that many standard antibiotic courses were longer than the data ever required.

Sources

• [s1] Short or Long Antibiotic Regimens in Orthopedics. New England Journal of Medicine. 16 September 2026.
• [s2] ClinicalTrials.gov. Short or Long Antibiotic Regimes in Orthopaedics (SOLARIO, NCT03806166). U.S. National Library of Medicine.